MARKET

PRVB

Provention Bio, Inc.
PRVB
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-7.7381
-
15.64
2,367,626,232.52
Tourlite Capital Management Q4 2023 Investor Letter
Tourlite Capital Management, LP is an asset management firm focused on long/short equity investing in public companies. Tourlite Fund, LP Founder Class returned 1.1% for the Fourth Quarter of 2023 and 8.8%. The fund has returned 14.3% since inception in April 2022.
Seeking Alpha · 01/27 09:45
UPDATE 1-France's Sanofi to buy U.S. drugs project INBRX-101 for about $2.2 bln
France's Sanofi to buy U.S. Drugs project INBRX-101 for about $2.2 bln. Sanofi agrees to buy the drug development project from its parent company Inhibrx Inc. The global pharmaceuticals sector has seen a wave of takeover deals in recent months.
Reuters · 01/23 06:29
UPDATE 1-Sanofi lifts earnings outlook on new drug launches, Dupixent sales
Reuters · 07/28/2023 06:15
Provention Bio gains after HSR waiting period for Sanofi deal expired
Seeking Alpha · 04/26/2023 13:11
Sanofi Announced Earlier: Hart-Scott-Rodino Waiting Period Expired For Sanofi's Acquisition Of Provention Bio
Benzinga · 04/26/2023 08:49
*Sanofi: All Other Terms and Conditions of Offer Remain Unchanged
Dow Jones · 04/26/2023 06:07
*Sanofi: Consummation of Offer Remains Subject to Various Conditions
Dow Jones · 04/26/2023 06:06
*Sanofi: Offer Is Scheduled to Expire Wednesday, May Be Extended
Dow Jones · 04/26/2023 06:06
More

Webull offers Provention Bio, Inc. stock information, including NASDAQ: PRVB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRVB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRVB stock methods without spending real money on the virtual paper trading platform.